Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
10 studies found for:    "membranoproliferative glomerulonephritis type II" OR "Glomerulonephritis, Membranoproliferative"
Show Display Options
Download search resultsDownload the search results for:
"membranoproliferative glomerulonephritis type II" OR "Glomerulonephritis, Membranoproliferative" (10 records)
Download Content:
zip file readers with free trial periods: WinZip and PKZip
Rank Status Study
1 Terminated Clinical Trial of CDX-1135 in Pediatric and Adult Patients With Dense Deposit Disease
Conditions: Dense Deposit Disease;   Membranoproliferative Glomerulonephritis Type II;   C3 Glomerulonephritis
Intervention: Drug: CDX-1135
2 Unknown  Eculizumab Therapy for Dense Deposit Disease and C3 Nephropathy
Conditions: Dense Deposit Disease;   Membranoproliferative Glomerulonephritis
Intervention: Drug: Eculizumab
3 Completed Pilot Study of Rituximab for Membranoproliferative Glomerulonephritis
Condition: Glomerulonephritis, Membranoproliferative
Intervention: Drug: Rituximab
4 Withdrawn Sulodexide Treatment in Patients With Dense Deposit Disease
Condition: Dense Deposit Disease
Intervention: Drug: Sulodexide
5 Active, not recruiting Eculizumab in Primary MPGN
Condition: Membranoproliferative Glomerulonephritis
Intervention: Drug: Eculizumab
6 Withdrawn TP10 Use in Patients With C3 Glomerulopathy (C3G)
Condition: Dense Deposit Disease
Intervention: Drug: TP10
7 Not yet recruiting Daratumumab in Treatment of PGNIMD and C3 GN
Condition: Membranoproliferative Glomerulonephritis
Intervention: Drug: Daratumumab
8 Not yet recruiting A Proof-of-Mechanism Study to Determine the Effect of ACH-0144471 on C3 Levels in Patients With C3G or IC-MPGN
Conditions: C3 Glomerulonephritis;   Dense Deposit Disease;   Membranoproliferative Glomerulonephritis, Type II;   C3 Glomerulopathy;   Immune Complex Mediated Membranoproliferative Glomerulonephritis
Intervention: Drug: ACH-0144471
9 Completed BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis
Conditions: Glomerulonephritis, Membranoproliferative;   Lupus Nephritis
Intervention: Drug: BG9588
10 Recruiting Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721
Conditions: IgAN;   Lupus Nephritis;   MN;   C3G
Interventions: Biological: OMS721;   Other: Vehicle (D5W)

Study has passed its completion date and status has not been verified in more than two years.